Circadian variation in MGMT promoter methylation and expression predicts sensitivity to temozolomide in glioblastoma. Gonzalez-Aponte MF, Huang Y, Leidig WA, Simon T, et al. J Neurooncol 2025;176:36.

Read + Share

Amedeo Smart

Independent Medical Education

Read + Share

Gonzalez-Aponte MF, Huang Y, Leidig WA, Simon T, et al. Circadian variation in MGMT promoter methylation and expression predicts sensitivity to temozolomide in glioblastoma. J Neurooncol 2025;176:36.
PMID: 41123669